Survival of de novo and secondary acute promyelocytic leukemia

A propensity-matched analysis of the SEER database

Smith Giri, Ranjan Pathak, Michael Martin, Vijaya Raj Bhatt

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Prior studies demonstrated that secondary acute promyelocytic leukemia (sAPL) and de novo APL may but not consistently have similar overall survival (OS). We used the Surveillance, Epidemiology, and End Results (SEER) 13 database to compare their OS. Patients with sAPL (n = 90), compared to de novo APL (n = 1600), were more likely to be older, White and diagnosed after year 2005. Mortality rate at 1 month (28.9% vs. 23.0%, p = 0.20) and 5-year OS (42% vs. 50%, p = 0.24) was similar between sAPL and de novo APL. In a multivariate analysis, sAPL was associated with similar OS as de novo APL (hazard ratio, HR 1.11; 95% confidence interval, CI 0.78-1.58; p = 0.546). This population-based study demonstrated no difference in OS or early mortality rate between sAPL and de novo APL. sAPL can be managed very similarly to de novo APL and does not need to be excluded from clinical trials of APL.

Original languageEnglish (US)
Pages (from-to)385-391
Number of pages7
JournalLeukemia and Lymphoma
Volume57
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Acute Promyelocytic Leukemia
Epidemiology
Databases
Survival
Mortality
Multivariate Analysis
Clinical Trials
Confidence Intervals
Population

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Survival of de novo and secondary acute promyelocytic leukemia : A propensity-matched analysis of the SEER database. / Giri, Smith; Pathak, Ranjan; Martin, Michael; Bhatt, Vijaya Raj.

In: Leukemia and Lymphoma, Vol. 57, No. 2, 01.02.2016, p. 385-391.

Research output: Contribution to journalArticle

@article{7170a46359ab4ef588e642d80fce35c1,
title = "Survival of de novo and secondary acute promyelocytic leukemia: A propensity-matched analysis of the SEER database",
abstract = "Prior studies demonstrated that secondary acute promyelocytic leukemia (sAPL) and de novo APL may but not consistently have similar overall survival (OS). We used the Surveillance, Epidemiology, and End Results (SEER) 13 database to compare their OS. Patients with sAPL (n = 90), compared to de novo APL (n = 1600), were more likely to be older, White and diagnosed after year 2005. Mortality rate at 1 month (28.9{\%} vs. 23.0{\%}, p = 0.20) and 5-year OS (42{\%} vs. 50{\%}, p = 0.24) was similar between sAPL and de novo APL. In a multivariate analysis, sAPL was associated with similar OS as de novo APL (hazard ratio, HR 1.11; 95{\%} confidence interval, CI 0.78-1.58; p = 0.546). This population-based study demonstrated no difference in OS or early mortality rate between sAPL and de novo APL. sAPL can be managed very similarly to de novo APL and does not need to be excluded from clinical trials of APL.",
author = "Smith Giri and Ranjan Pathak and Michael Martin and Bhatt, {Vijaya Raj}",
year = "2016",
month = "2",
day = "1",
doi = "10.3109/10428194.2015.1063142",
language = "English (US)",
volume = "57",
pages = "385--391",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Survival of de novo and secondary acute promyelocytic leukemia

T2 - A propensity-matched analysis of the SEER database

AU - Giri, Smith

AU - Pathak, Ranjan

AU - Martin, Michael

AU - Bhatt, Vijaya Raj

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Prior studies demonstrated that secondary acute promyelocytic leukemia (sAPL) and de novo APL may but not consistently have similar overall survival (OS). We used the Surveillance, Epidemiology, and End Results (SEER) 13 database to compare their OS. Patients with sAPL (n = 90), compared to de novo APL (n = 1600), were more likely to be older, White and diagnosed after year 2005. Mortality rate at 1 month (28.9% vs. 23.0%, p = 0.20) and 5-year OS (42% vs. 50%, p = 0.24) was similar between sAPL and de novo APL. In a multivariate analysis, sAPL was associated with similar OS as de novo APL (hazard ratio, HR 1.11; 95% confidence interval, CI 0.78-1.58; p = 0.546). This population-based study demonstrated no difference in OS or early mortality rate between sAPL and de novo APL. sAPL can be managed very similarly to de novo APL and does not need to be excluded from clinical trials of APL.

AB - Prior studies demonstrated that secondary acute promyelocytic leukemia (sAPL) and de novo APL may but not consistently have similar overall survival (OS). We used the Surveillance, Epidemiology, and End Results (SEER) 13 database to compare their OS. Patients with sAPL (n = 90), compared to de novo APL (n = 1600), were more likely to be older, White and diagnosed after year 2005. Mortality rate at 1 month (28.9% vs. 23.0%, p = 0.20) and 5-year OS (42% vs. 50%, p = 0.24) was similar between sAPL and de novo APL. In a multivariate analysis, sAPL was associated with similar OS as de novo APL (hazard ratio, HR 1.11; 95% confidence interval, CI 0.78-1.58; p = 0.546). This population-based study demonstrated no difference in OS or early mortality rate between sAPL and de novo APL. sAPL can be managed very similarly to de novo APL and does not need to be excluded from clinical trials of APL.

UR - http://www.scopus.com/inward/record.url?scp=84955213307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955213307&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1063142

DO - 10.3109/10428194.2015.1063142

M3 - Article

VL - 57

SP - 385

EP - 391

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -